Research programme: cytokine therapeutics - Werewolf Therapeutics
Alternative Names: INDUKINES™Latest Information Update: 28 Dec 2023
At a glance
- Originator Werewolf Therapeutics
- Class Anti-inflammatories; Antineoplastics; Cytokines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation
- No development reported Cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 31 Dec 2022 Early research in Autoimmune disorders in USA (Parenteral) before December 2022 (Werewolf Therapeutics, May 2023)
- 31 Dec 2022 Early research in Inflammation in USA (Parenteral) before December 2022 (Werewolf Therapeutics, May 2023)